Evidence map›Paper›PMID 33106487›Full record

ArticleScientific reports2020

Prediction of the binding interface between monoclonal antibody m102.4 and Nipah attachment glycoprotein using structure-guided alanine scanning and computational docking.

Phanthakarn Tit-Oon, Kannan Tharakaraman, Charlermchai Artpradit, Abhinav Godavarthi, Pareenart Sungkeeree, Varun Sasisekharan, Jarunee Kerdwong, Nathaniel Loren Miller, Bhuvna Mahajan, Amnart Khongmanee and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Learned features of antibody-antigen binding affinity.Frontiers in molecular biosciences · 2023
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Phanthakarn Tit-OonTranslational Research Unit, Chulabhorn Research Institute, Bangkok, 10210, Thailand.
Kannan TharakaramanKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Charlermchai ArtpraditTranslational Research Unit, Chulabhorn Research Institute, Bangkok, 10210, Thailand.
Abhinav GodavarthiTranslational Research Unit, Chulabhorn Research Institute, Bangkok, 10210, Thailand.
Pareenart SungkeereeTranslational Research Unit, Chulabhorn Research Institute, Bangkok, 10210, Thailand.
Varun SasisekharanTranslational Research Unit, Chulabhorn Research Institute, Bangkok, 10210, Thailand.
Jarunee KerdwongTranslational Research Unit, Chulabhorn Research Institute, Bangkok, 10210, Thailand.
Nathaniel Loren MillerKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Bhuvna MahajanTranslational Research Unit, Chulabhorn Research Institute, Bangkok, 10210, Thailand.
Amnart KhongmaneeTranslational Research Unit, Chulabhorn Research Institute, Bangkok, 10210, Thailand.
Mathuros RuchirawatTranslational Research Unit, Chulabhorn Research Institute, Bangkok, 10210, Thailand.
Ram SasisekharanKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA. rams@mit.edu.
Mayuree FuangthongTranslational Research Unit, Chulabhorn Research Institute, Bangkok, 10210, Thailand. mayuree@cri.or.th.
Chulabhorn Research Institute · THMassachusetts Institute of Technology · USHarvard–MIT Division of Health Sciences and Technology · US

Funding

TRAINING GRANTS IN ENVIROMENTAL TOXICOLOGYT32ES007020 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ESSIGMANN, JOHN M · 1985 to 2024
$13.1M
NIEHS NIH HHS T32 ES007020
6 · The paper itself

Abstract

Nipah Virus (NiV) has been designated as a priority disease with an urgent need for therapeutic development by World Health Organization. The monoclonal antibody m102.4 binds to the immunodominant NiV receptor-binding glycoprotein (GP), and potently neutralizes NiV, indicating its potential as a therapeutic agent. Although the co-crystal structure of m102.3, an m102.4 derivative, in complex with the GP of the related Hendra Virus (HeV) has been solved, the structural interaction between m102.4 and NiV is uncharacterized. Herein, we used structure-guided alanine-scanning mutagenesis to map the functional epitope and paratope residues that govern the antigen-antibody interaction. Our results revealed that the binding of m102.4 is mediated predominantly by two residues in the HCDR3 region, which is unusually small for an antibody-antigen interaction. We performed computational docking to generate a structural model of m102.4-NiV interaction. Our model indicates that m102.4 targets the common hydrophobic central cavity and a hydrophilic rim on the GP, as observed for the m102.3-HeV co-crystal, albeit with Fv orientation differences. In summary, our study provides insight into the m102.4-NiV interaction, demonstrating that structure-guided alanine-scanning and computational modeling can serve as the starting point for additional antibody reengineering (e.g. affinity maturation) to generate potential therapeutic candidates.

Indexed as

Computer SimulationAlanineAnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntigen-Antibody ComplexEpitopesGlycoproteinsHenipavirus InfectionsHumansMutagenesis, Site-DirectedNipah VirusProtein Structural ElementsViral Envelope ProteinsAlanineAntibodies, MonoclonalAntibodies, NeutralizingAntigen-Antibody ComplexEpitopesGlycoproteinsViral Envelope Proteins

Identifiers

PMID33106487
PMCPMC7588459
OpenAlexW3094374473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.